MGX logo

MGX Metagenomi, Inc. Common Stock

NASDAQ Global Select · Biotechnology · Healthcare

$0.56
-0.05 (-7.95%)

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration s…

Market Cap: $21.36Mwww.metagenomi.co

Price

No data yet.

Social Signal Score

51
5d
70
1 mentions
—
30d
43
3 mentions
—
60d
45
4 mentions
—
90d
46
5 mentions
—
news: 5

Analyst Ratings

5 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 1Sell 0Strong Sell 0
Avg price target$14.5+2466.4%
Low $7Median $14.5High $22
Current Consensus

Revenue

$2.18M-34.73%
$-257.0K$6.50M$13.25M$20.01M
Mar 2022Sep 2026

Analyst Estimates

FY2025
$-2.36
$-2.50–$-2.18
3 analysts
FY2026
$-2.50
$-2.62–$-2.26
3 analysts
FY2027
$-1.91
$-2.12–$-1.79
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jian Irish
Sector
Healthcare
Industry
Biotechnology
Employees
113
Beta
0.67
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-4.53
www.metagenomi.co